CARDOZA GEORGE purchased $141K of SOPH

CARDOZA GEORGE (Chief Financial Officer) purchased 20,000 shares of SOPHiA GENETICS SA (SOPH) at $7.06 ($0.14M total) on 2026-11-06.

Original reporting
SEC EDGAR · CARDOZA GEORGE
Published Nov 9, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Bullish
medium confidence
Mentioned
$SOPH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHBullishLow
01

Why it matters

The CFO's purchase adds a modest amount of shares to his stake, potentially signaling confidence but unlikely to move the stock significantly.

02

Market read

A small insider purchase that may generate slight positive sentiment but has limited trading relevance.

03

What to watch

The CFO's buy could be driven by personal tax planning rather than confidence in the business.

Relevance 5/10Novelty 4/10Timing: post-market today

Background

SEC Form 4 filings disclose insider transactions and are primary sources for corporate insider activity.

Company-level read

Ticker impact

$SOPHBullishMedium confidence
Context

CFO Cardoza George bought 20,000 SOPH shares for $141,200 on 2026-11-06, raising his holding to 326,726 shares.

Expected impact

likely modest upward pressure as investors interpret the CFO's buy as a positive signal

Evidence & confidence

The transaction size is small relative to market cap, but insider buying is generally viewed favorably.

Market effects

Minimal impact on the broader biotech sector; insider activity is company‑specific.

No discernible regional effect; the filing is a routine U.S. SEC disclosure.

Limited global relevance; only investors in SOPH may adjust positions.

Counterpoint

The purchase may be routine portfolio rebalancing and not a strong endorsement of future performance.

Key entities

  • SOPHiA GENETICS SA

    Swiss biotech firm listed on NASDAQ under the ticker SOPH.

  • Cardoza George

    Chief Financial Officer of SOPHiA GENETICS SA.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September